Eli Lilly and Co. on Wednesday appointed a new chief for its diabetes and obesity unit in a string of leadership changes ahead of a key regulatory decision on the use of its potential blockbuster drug Mounjaro as a weight-loss treatment.
Eli Lilly on Tuesday announced it is acquiring Point Biopharma in an effort to bolster its cancer business with the Pennsylvania-based company’s pipeline of clinical and preclinical radioligand therapies.
The FDA has rejected Eli Lilly’s investigational antibody lebrikizumab for the treatment of moderate-to-severe atopic dermatitis due to manufacturing problems, the company announced on Monday.
The company and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs, according to court filings.
The US Food and Drug Administration received more than 250 reports of patients experiencing suicidal thoughts or behaviors while taking Ozempic or similar medicines since 2010, Reuters found in an examination of the FDA’s adverse-event database.
Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly’s migraine drug Emgality infringed three patents related to Teva’s rival drug Ajovy.
The National Institute for Health and Care Excellence (NICE) said in draft final guidance that it estimates some 180,000 people could benefit from the new treatment.
Two U.S. senators are demanding that the nation’s three largest insulin makers, Novo Nordisk (NOVOb.CO), Eli Lilly (LLY.N), and Sanofi (SASY.PA), provide details by Sept. 15 of their programs to help Americans get their insulin for $35 a month or less.
Novo Nordisk has again bought a weight-loss focused biotech, as the obesity market heats up. Announced Wednesday, the Danish pharma plans to buy Embark Biotech for $16.3 million up front with close to $500 million on the line in milestone payments—Novo’s second obesity-focused acquisition in three weeks.
A first-in-human Phase I trial showed that Eli Lilly’s investigational oral lipoprotein(a) inhibitor muvalaplin was safe and could elicit sharp reductions in concentrations of cholesterol formation.